Pharma giant GSK is quitting BIO in latest setback for the lobbying group

Taking stock of the drug industry, from the lab to the medicine chest

November 8, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

JUSTIN TALLIS/AFP via Getty Images STAT+ | Pharma giant GSK is quitting BIO in latest setback for the lobbying group GSK is the fifth biopharma company to depart BIO in about a year. The departures coincided with a drop in lobbying spending from the group. By John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle What Trump and Robert F. Kennedy Jr. might do to undermine vaccines — and what they likely can't RFK Jr. may push the FDA to gather more data, and could try to fill the CDC's Advisory Committee on Immunization Practices with vaccine skeptics. By Lizzy Lawrence and Timmy Broderick STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman JIM WATSON/AFP via Getty Images Health and science experts on their hopes and worries for the Trump era Health and science experts react to Trump's win: Cautious optimism on chronic disease issues, some deep worries on scientific integrity and research. By Elizabeth Cooney, Isabella Cueto, Usha Lee McFarling, Anil Oza, and Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser